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Abstract 
Agmatine (1-amino-4-guanidinobutane), a precursor for polyamine biosynthesis, 
has been identified as an important neuromodulator with anticonvulsant, antineurotoxic and 
antidepressant actions in the brain. In this context it has emerged as an important mediator 
of addiction/satiety pathways associated with alcohol misuse. Consequently, the regulation 
of the activity of key enzymes in agmatine metabolism is an attractive strategy to combat 
alcoholism and related addiction disorders. 
Agmatine results from the decarboxylation of L-arginine in a reaction catalyzed by 
arginine decarboxylase (ADC), and can be converted to either guanidine butyraldehyde by 
diamine oxidase (DAO) or putrescine and urea by the enzyme agmatinase (AGM) or the 
more recently identified AGM-like protein (ALP).  In rat brain, agmatine, AGM and ALP 
are predominantly localised in areas associated with roles in appetitive and craving (drug-
reinstatement) behaviors. Thus, inhibitors of AGM or ALP are promising agents for the 
treatment of addictions. In this review, the properties of DAO, AGM and ALP are 
discussed with a view to their role in the agmatine metabolism in mammals. 
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Introduction 
Agmatine (1-amino-4-guanidinobutane) is a primary amine that is generated from 
the decarboxylation of L-arginine by arginine decarboxylase (ADC; EC 4.1.1.19: Fig. 1). In 
mammals, agmatine has been directly associated with many important cellular functions, 
including the modulation of insulin release from pancreatic cells [1-3], renal sodium 
excretion [4,5] and neuroprotective effects [6-9]; furthermore, agmatine inhibits all known 
isoforms of nitric oxide synthase (NOS) in the brain [10] and increases the tolerance to 
morphine [11]. Agmatine also plays an essential role in the regulation of the expression of 
ornithine decarboxylase (ODC) [12] (Fig.1) and spermidine/spermine acetyl transferase 
[13], two enzymes that are involved in polyamine biosynthesis [14]. In the central nervous 
system (CNS), agmatine is considered to be a neurotransmitter/neuromodulator, because it 
is synthesized in the brain, stored in synaptic vesicles, accumulated by uptake and released 
by depolarization [15,16]. In addition, agmatine activates several membrane receptors, 
including nicotinic, imidazoline, α2-adrenergic, 5-HT2A, and 5HT3 [16], while it 
antagonizes N-methyl-D-aspartate (NMDA) receptors [16-19]. It also regulates the release 
of catecholamines and potentiates opioid analgesia [20]. However, a receptor specific for 
agmatine has not yet been described. 
Agmatine administration to laboratory rodents modulates ethanol-induced 
anxiolysis and withdrawal anxiety [21], nicotine sensitization, and compulsive behaviors 
[21-23]. Injection of agmatine also produces anticonvulsant, antineurotoxic, and 
antidepressant-like actions in animals [24-27]. In recent years the number of studies with 
animal models has increased; these have demonstrated beneficial effects of agmatine 
administration for the following disorders: anxiety, hypoxic ischemia, nociception, 
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morphine tolerance, memory loss, Parkinson’s disease, Alzheimer’s disease, traumatic 
brain injury-related disorders, and epilepsy [17,28-32]. Furthermore, an increase in 
intracellular agmatine concentration has been associated with a decrease in the number of 
neoplastic cells. RNA interference targeting ADC resulted in a significant increase in 
proliferation of the human intestinal tumor cell line SW480, which was paralleled by a 
distinct decrease of the intracellular agmatine content [33]. On the other hand, addition of 
ADC to the culture medium of HeLa cells caused the arrest of cell growth [34]. These 
observations may be linked to the inhibitory effect of agmatine on ODC [35,36] and 
polyamine uptake [37-39], because ODC is the rate-limiting enzyme in polyamine synthesis 
and polyamines are required for a cell to enter into the cell cycle and to proliferate. 
The cellular and regional distributions of agmatine were mapped in rat brain with 
the aid of a polyclonal anti-agmatine antibody [40]. The highest numbers of neurons 
displaying agmatine immunoreactivity were in hippocampus, hypothalamus, and the rostral 
midbrain, as well as in periventricular areas that included the dorsolateral nucleus, locus 
cœruleus, nucleus raphe dorsalis and the periaqueductal gray matter [40]. Notably, 
agmatine-containing neurons were concentrated in regions of the brain that regulate 
visceral and neuroendocrine control, the processing of emotions, pain perception, and 
cognition [15,16]. 
The capacity of rat brain to synthesize agmatine has been also investigated. The 
highest levels of ADC activity were detected in hypothalamus and cerebral cortex, while 
the lowest levels were found in the locus cœruleus and medulla [41,42]. ADC is also 
present in various other tissues and/or organs, with the highest levels recorded in the aorta 
and the lowest in testis [43]. ADC, extracted from rat brain mitochondrial preparations, is 
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thermally unstable but able to catalyze the decarboxylation of both arginine (Km ~0.75 mM) 
and ornithine (Km ~0.25 mM), in a reaction that is not inhibited by the specific ODC 
inhibitor difluoromethylornithine [43]. Agmatine is thus synthesized in proximity to 
mitochondria, and to a class of imidazoline receptors (I2) to which agmatine binds with 
high affinity [16,44]; indeed, while there is evidence for the localization of I2 on synaptic 
membranes, a higher proportion of I2 is found on mitochodrial membranes [45]. In rat 
liver, ADC is also associated with the mitochondrium; its Km value for arginine is 28-40 
mM [46]. The importance of ADC in agmatine biosynthesis has been demonstrated with 
various cell models, in which agmatine could be detected upon transfection with the ADC-
encoding gene [47-49]. However, since no data on the kinetic properties of isolated ADC 
are currently available, further studies are necessary to develop a better understanding of 
the role of this enzyme in the agmatine metabolism. 
While only one enzyme appears to be involved in the formation of agmatine, several 
contribute to its degradation (Fig. 1). In one route agmatine is converted to 
guanidinobutyraldehyde by diamine oxidase (DAO), while in another path it is hydrolyzed 
to putrescine and urea by either agmatinase (AGM) or the more-recently described AGM-
like protein (ALP).  Guanidinobutyraldehyde is a precursor for the neurotransmitter 4-
aminobutyrate (GABA) [50], whereas putrescine is a precursor for polyamines, which are 
essential for proliferation, differentiation and migration of mammalian cells and also act as 
positive modulators of glutamate-NMDA receptors. In addition, putrescine in the brain can 
also be converted via aminobutanal to GABA by the combined action of monoamine 
oxidases (MAOs) or DAOs and aldehyde dehydrogenase, respectively [51]. Aldehyde 
dehydrogenase 1A1 mediates a GABA synthesis pathway in midbrain dopaminergic 
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neurons; glial GABA, synthesized by MAO B, mediates tonic inhibition [52,53]. These 
pathways and those outlined in the next section may allow agmatine to participate 
indirectly in GABA-mediated inhibition in the brain, and thus augment its direct action as 
an inhibitor neurotransmitter. GABA is metabolized to succinate and thereby enters the 
citric acid cycle via succinate semialdehyde and its dehydrogenase, which is a target of the 
target of the antiepileptic valproate. Hence, augmentation of GABA concentration may 
contribute to agmatine’s anticonvulsant activity (as mentioned above). 
Diamine oxidase (DAO) 
DAO (EC 1.4.3.6) catalyzes the conversion of agmatine to guanidinobutyraldehyde 
(Fig. 1), which is subsequently (i) oxidized to guanidinobutyrate by an aldehyde 
dehydrogenase, and (ii) then hydrolyzed to 4-amino butyrate (GABA) by a ureohydrolase; 
such an enzyme was initially identified in liver, kidney and intestinal mucosa samples from 
rabbit, and more recently in human brain samples [50,54,55]. DAO has been identified in 
various mammalian tissues, including the basal level of the skin epidermis, glomeruli, the 
decidua of the placenta, epithelial cells in the small intestine, blood and tissue eosinophils, 
macrophages, as well as smooth muscle cells of veins, arteries, bronchioles, stomach wall 
and skin [56]. Its distribution, detected by immunohistochemistry, is identical in human and 
mouse tissues [56]. Enzymatic activity assays and Northern blot analysis of guinea pig 
tissues indicate that the relative abundance of the enzyme is liver > small intestine > lung, 
kidney > stomach [57]. Only small but detectable amounts of DAO mRNA were observed 
in cerebellum, thalamus-hypothalamus and cerebral cortex [57]. As these distribution data 
suggest, the role of DAO is not specific for agmatine metabolism in the brain. Indeed, DAO 
purified from porcine kidney, not only acts on agmatine (Km ~5 µM), but also on histamine 
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(Km ~15 µM), putrescine (Km ~0.2 mM) and spermidine (Km ~1 mM) [50], and because it 
was originally identified for its ability to remove exogenous histamine from lung and liver 
samples it is also designated as histaminase [56]. Reduced levels of DAO are directly 
correlated with histamine intolerance [58], and inhibitors such as berenil and pentamidine 
are diamine derivatives used as drugs to treat Trypanosomiasis and Pneumocystis 
pneumoniæ [59,60]. The low prevalence of DAO in brain, together with its function as 
target for chemotherapeutics to treat infectious diseases, reduce the suitability of this 
enzyme as target for inhibitors that are geared towards treating addiction-related disorders. 
Agmatinase (AGM) 
AGM (EC 3.5.3.1.1) catalyzes the hydrolytic breakdown of agmatine to putrescine 
and urea (Fig. 1). In mammals, agmatine hydrolysis has been directly determined only in 
rat brain [61,62] and murine macrophages [63]. In subcellular fractions of rat brain, AGM 
activity has been associated principally to mitochondrial fractions. Distributed in the 
hypothalamus, medulla oblongata and hippocampus, and significantly lower levels in the 
striatum and the cerebral cortex of rat brain [61]. Generally, the reported values of AGM 
activity in the rat brain are extremely low (7.6–11.8 nmol urea/mg of protein/h), almost at 
the limit of sensitivity of the methods used [61,62] and the enzyme has not been purified.  
The cloning and partial characterization of human AGM was reported almost 
simultaneously by two different groups [64, 65]. The protein shares 35% sequence identity 
with Escherichia coli AGM, requires Mn
2+
 for activity and, importantly, all the side chains 
essential for metal ion and substrate binding  in members of the ureohydrolases 
superfamily, which include all known bacterial AGMs, arginases, ureases and some 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
8 
 
organophosphate-degrading hydrolases [66-70], are conserved (Fig. 2). Interestingly, AGM 
has an N-terminal mitochondrial import sequence, and the enzyme’s mitochondrial 
localization has indeed been confirmed in kidney cells [71]. Due to the extremely low 
catalytic activity of isolated, recombinant mammalian AGMs, little is currently known 
about their enzymatic properties [64,65]. The strongest demonstration of their AGM 
activity has come from a functional complementation test, not from a direct in vitro 
enzymatic assay. The test is based on the polyamine-requiring yeast strain yASG1–8 that 
contains a disruption in the spe1 gene encoding ODC, which makes the cells fully 
dependent on exogenous polyamines for growth [65,72]. Transformants of yASG1–8, 
expressing either E. coli ADC (encoded by the gene speA) or E. coli AGM (speB) also 
require exogenous polyamines, but the simultaneous expression of both genes, speA and 
speB, allows the yeast strain to grow on minimal medium without exogenous polyamines. 
Yeast strain transfected with mouse AGM or human AGM grew in minimal medium, 
compared with the non-transfected strain (Fig. 3). Using the structure of rat arginase I as 
template, a homology model for human AGM was generated (the sequence identity 
between the two proteins is 20%) [64].  The modelled structure reveals significant 
structural homology, in particular in domains that are conserved in most ureahydrolases; 
these include an active site that can accommodate two closely spaced divalent metal ions 
(i.e. a di-managanese cluster) [64] . It is intriguing, however, that although preliminary 
crystallographic data of human AGM were reported, its structure has not yet been resolved 
[73]. Furthermore, isolated recombinant mammalian AGMs appear to lack metal ions [72]. 
These observations may indicate that mammalian AGMs adopt a fold different from that of 
their bacterial counterparts or the distantly related arginases. Indeed, while a sequence 
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comparison indicates that human AGM may have active site residues (i.e. manganese-
coordinating residues) identical to those of other ureahydrolases, four out of these six 
residues are different in mouse AGM [72]. Indeed, if the predicted fold of mammalian 
AGMs were correct at least the mouse enzyme would not be expected to bind metal ions in 
its active site with high affinity since the four substitutions involve the replacement of side 
chains that form strong interactions with metal ions with residues that form either weak or 
no coordination bonds at all [72]. It has been speculated that mammalian AGMs require 
cofactors or chaperones similar to the Ni
2+
-dependent urease to form an active, Mn
2+
-
containing form [72]. The identification of such cofactors will be essential to understand 
the regulation of mammalian AGMs and thus their role(s) in controlling the agmatine 
metabolism. 
In human tissues, AGM mRNA is most abundant in liver and kidney, with much 
lower expression levels observed in muscle, small intestine, and brain [64]. Similarly, 
Western blot analysis has demonstrated that AGM is most abundant in the liver, with lower 
amounts present in the thalamus, cerebellum and cerebral cortex of rat brain [74]. The use 
of immunocytochemical methods showed that in human and rat brain AGM is 
predominantly present in distinct populations of neurons, especially cortical interneurons. 
Principal neurons in limbic regions such as the habenula, and in cerebellum, also express 
AGM [74]. In contrast, a proteomics approach showed that human AGM is diminished in 
the clear-cell type of renal carcinoma, an observation that is consistent with a reduced 
amount of AGM mRNA in such tumor cells [71]. AGM levels vary in mood disorders: 
human subjects affected by depression show reduced blood levels of agmatine, which is 
consistent with post-mortem findings of increased AGM levels in brain tissues from 
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depressed subjects [75,76]. The correlation between AGM/agmatine levels and mood was 
also illustrated in a mouse model of depression. An AGM upregulation in the prefrontal 
cortex and hippocampus was demonstrated by confocal immunofluorescence microscopy, 
notably in parvalbumin- and somatostatin-positive interneurons [77]. 
In summary, AGM is a poorly understood, Mn
2+
-dependent ureohydrolase. Its 
inverse correlation with agmatine levels in brain tissue, together with its complex 
regulatory mechanism requiring as-yet unidentified cofactors or chaperones, make this 
enzyme an interesting target for the development of novel chemotherapeutics to treat 
neurological disorders. 
Agmatinase-like protein (ALP) 
Recently, a novel enzyme with AGM activity was cloned from a rat brain cDNA 
library, the AGM-Like Protein (ALP) [78-82]. However, its amino acid sequence bears no 
resemblance to known AGMs (from any source) nor to other ureohydrolases; no motif that 
may define the active site of this enzyme has yet been identified [69]. ALP is specific for 
the substrate agmatine, and is not active against arginine. Using a polyclonal antibody 
raised against ALP was shown to be localized mainly in astrocytes and neurons in rat 
hypothalamus and hippocampus [80]. Recombinant ALP expressed in E. coli and purified, 
is the first (and to date only) mammalian enzyme with in vitro AGM activity (kcat ~1.0 s
-1
; 
Km ~3.0 mM for agmatine [78,79]. The ability of ALP to generate putrescine (Fig. 1) for 
polyamine synthesis, has also been demonstrated using the same complementation assay 
that was employed to demonstrate biological activity of mammalian AGMs in a yeast strain 
(see above and compare Figs 3 and 4) [72,79,81].  
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In addition to being active in isolated form ALP is distinct from mammalian AGMs 
in the regulation of its catalytic activity. The C-terminal section of the protein (residues 
459–510) comprises the sequence motif C-X16-H-X2-C-X2-C-X2-C-X21-C-X2-C), 
characteristic of the LIM domain, a fold that plays important roles in protein-protein 
interactions [81]. Such domains are key components of the regulatory machinery of cells. 
Specifically, LIM domain-containing proteins have been implicated in cellular 
differentiation and the control of cell growth, and play crucial roles in cytoarchitecture, cell 
adhesion, cell motility and signal transduction, and as regulators of gene expression 
[83,84]. The LIM domain folds into two zinc fingers, each stabilized at its base by a Zn
2+
 
ion [81]; a homology model for the LIM domain of rat brain ALP is shown in Fig. 5 [82]. 
Notably, a deletion mutant of rat brain ALP that lacks the LIM domain is catalytically 
significantly more efficient than its wild-type counterpart; the truncated variant has a ten-
fold higher kcat and a three-fold lower Km value for agmatine [81]. The altered kinetic 
parameters of the truncated mutant are accompanied by significant alterations in tryptophan 
fluorescence, which indicate that a lack of the LIM domain also affects overall ALP 
structure [81]. These structural changes are unlikely to be irreversible because addition of 
the isolated LIM domain to the truncated rat brain ALP variant restores the catalytic 
properties of the wild-type enzyme [82]. Mutation of one of the Zn
2+
 binding sites 
(replacement of Cys453 by Ala) leads to a similar degree of activation of catalytic 
efficiency as the complete removal of the LIM domain [82]. A similar activation 
mechanism was observed in a LIM domain-containing kinase; complete removal of the 
LIM domain or introduction of a specific Cys mutation also enhanced this enzyme’s 
catalytic efficiency [85]. The LIM domain thus appears to act as an auto-inhibitory entity in 
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ALP; we speculate that the interaction of this domain with an as-yet unknown accessory 
protein may abolish this inhibition, thus providing an alternative avenue for the regulation 
of agmatine levels in the brain.  
In the section above the relevance of Zn
2+
 for the regulation of ALP activity was 
discussed. However, the enzyme also requires Mn
2+
 for catalytic activity, as evidenced by 
its complete inactivation when incubated with the metal ion chelator EDTA. The enzymatic 
activity can, however, easily be recovered by the addition of Mn
2+
 to the metal-ion-free 
apoenzyme [82,86]. In this respect ALP behaves like all well-characterized Mn
2+
-
dependent members of the ureohydrolase family, which include human and rat arginases 
[87,88] and bacterial AGMs [65,66]. In their fully active states the active sites of arginases 
and bacterial AGMs contain a binuclear Mn
2+
 center. Crystal structures of Deinococcus 
radiodurans AGM [89] and the two putative AGMs from Clostridium difficile and 
Burkholderia thailandensis [90] have been reported (Fig. 6). These structures provide 
detailed insight into the active site of bacterial AGMs, which is virtually identical to those 
of arginases (as expected from the sequence homology shared by these enzymes). The lack 
of sequence homology between these enzymes and ALP limits, in part, our current 
knowledge of the structure of the active site of the latter. Metal-ion measurements indicate 
that ALP is likely to contain a bimetallic manganese center in its catalytically optimal form 
[82,86]. Mutagenesis studies identified up to two Histidine residues that play important 
roles in Mn
2+
 binding in ALP, but the precise structure of the bimetallic metal center awaits 
further structural studies [86]. 
The form of ALP initially obtained is encoded by a 1569 bp cDNA, but two 
additional transcripts with extended 5'-regions have since been detected. These are denoted 
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LIMCH1 isoforms I (3918 bp) and II (2871 bp); their 3'-regions are identical to that of their 
shorter counterpart [79]. Interestingly, in isoform I the N-terminal region is characteristic of 
a calponin homology (CH) domain. CH domains occur in three highly divergent groups: 
CH1 and CH2 bind actin, while CH3, present in LIMCH1 isoform I, binds to microtubules 
[91]. Despite their N-terminal extensions both LIMCH1 isoforms I and II catalyze the 
hydrolysis of agmatine and support polyamine biosynthesis in vivo (Fig. 4). In addition, 
removal of the C-terminal LIM-domain in these isoforms produces a moderate activation, 
albeit to an extent less significant than observed for their shorter counterpart [79]. Splicing 
mechanisms that may lead to different ALP variants in rat brain have not yet been 
investigated but it is likely that isoform I is the initial functional enzyme produced there, 
while isoform II and the shorter homolog represent proteolytically modified forms. 
Understanding the mechanism of protein processing of ALP will be essential to fully 
comprehend the role of this enzyme in brain metabolism, and to target it for the 
development of novel treatments for neurological disorders such as alcoholism. In the 
human genome there is a single sequence (accession code: Q9UPQO) that encodes a 
putative enzyme which is 85% identical to rat brain LIMCH1 isoform I; their C-terminal 
LIM domains share 98% identity. Preliminary data by our group indeed demonstrate that 
this human homolog of ALP indeed possesses AGM activity (unpublished data). 
Conclusions 
In 2004, Morris stated that in mammals the “agmatine metabolism is still largely a 
mystery” [92]. At present, the cloning and partial characterization of ADC and the enzymes 
involved in agmatine degradation (Fig. 1) have significantly enhanced our knowledge of 
the agmatine metabolism in particular in mammals. However, questions remain. For 
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instance, it is not known why mammalian AGMs are virtually inactive under in vitro 
conditions. It is speculated that the enzymes may adopt a fold different from that of their 
bacterial counterparts and other members of the ureohydrolase family, and that they are 
activated by protein-protein interactions in the cell as occurs with the Ni
2+
-dependent 
urease [93]. This mechanism could provide the practical base for an efficient strategy to 
control AGM activity, and in turn agmatine concentrations. However, since AGM is not 
highly abundant in brain tissues it appears that this enzyme is unlikely to play a major role 
in this organ. In contrast, ALP is mostly found in the brain. Not only is this unusual enzyme 
an efficient AGM under in vitro and biological conditions, but its activity can be modulated 
via a C-terminal zinc finger (LIM) domain. Currently, only ALP from rat brain tissue has 
been partially characterized. While the enzyme requires manganese for its catalytic function 
its active-site geometry and metal-ion stoichiometry have not yet been determined.  Also, 
possible accessory proteins that may regulate the activity of the enzyme via interaction with 
its LIM domain have not yet been identified. Addressing these current gaps in knowledge 
will be crucial for establishing ALP as a drug target, a role that is supported by the 
predominant co-localization of agmatine and ALP in rat brain areas associated with 
appetitive and craving (drug-reinstatement) behaviors [79,80,94]. Agmatine is considered 
relatively safe when taken orally but has a range of actions outside the brain [95,96]. An 
inhibitor of ALP (and possibly AGM) is anticipated to have an effect similar to that of 
exogenous agmatine injection (which reduces ethanol-withdrawal anxiety in rodents), but 
by targeting a specific pathway a lower risk of side effects is expected (Fig. 7). 
Knowing where the agmatine receptor is localised in the brain is critical for 
understanding its function. This localisation is currently not known in either healthy 
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controls or individuals suffering from alcohol misuse. A PET ligand for the agmatine 
receptor IR2, [
11
C]BU99008, has recently been developed [97]. It has high specificity and 
behaves well in in vivo imaging in primates [98]. 
In summary, agmatine offers a much-needed new avenue to address disorders such 
as alcohol misuse and related addictions [99]. The human and financial costs associated 
with alcoholism alone are enormous and novel treatment strategies are urgently needed. 
Annually, several million people die of alcohol misuse [100]. Treatment options are 
limited; currently approved drugs for treating alcoholism have questionable efficacy and 
limited uptake in the community [101]. AGM, and in particular ALP, are promising targets 
for new strategies to address this global problem. 
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Figure legends 
Figure 1. Metabolic pathways for agmatine synthesis and conversion to polyamines or 
GABA. Agmatine, produced from L-arginine by ADC, may be hydrolyzed to putrescine, 
either by AGM or ALP in the polyamine biosynthetic pathway, or converted to 
guanidinobutyraldehyde by DAO, for the synthesis of GABA. ODC decarboxylates 
arginine and is also capable to produce putrescine. 
 
Figure 2. Multiple sequence alignment of human, E. coli, D. radiodurans agmatinases and 
human arginase. Sequences obtained from Uniprot were aligned by Clustal Omega and 
displayed using the GeneDoc. Locations of the three histidines and four  aspartate residues, 
required for metal ligand binding and enzymatic activity, which are conserved among 
members of the ureohydrolase superfamily, are indicated by stars below the alignment. 
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Figure 3. The cell growth of yeast strains unable to polyamine biosynthesis transfected 
with AGM mouse (i.e. clone 1 (□) and 2 (■)) and human AGM (▲), compared with the 
non-transfected strain (●). The yeast strain lacks the ODC gene, making it deficient in 
polyamine biosynthesis and necessitating the presence of exogenous polyamines for 
growth. The cultures were depleted of endogenous polyamines and then grown in minimal 
medium. All media contained 10 μg/mL agmatine and growth was estimated by 
nephelometry at 600 nm.  The data were previously published [72] and reproduced with 
permission from the Journal of Inorganic Biochemistry. 
 
Figure 4. Yeast strains unable to polyamine biosynthesis, transfected with isoform I of the 
Limch1 gene (o); Yeast transformed with isoform II of the Limch1 gene (o); yeast 
transformed with the ALP gene (□); untransformed control cells (●). After 30 h, spermidine 
was added to the control culture to verify the viability and dependence of polyamines for 
growth of this yeast strain. All other details are identical to those described for Fig. 3 (see 
for more details [79]). 
 
Figure 5.  Homology model of the LIM domain of ALP. Left, schematic representation of 
the LIM-domain of ALP. (A), structural model of the LIM-domain of ALP, constructed 
using MODELLER 9v10. (B) and (C), geometric environments of the Zn
2+
 ions in the two 
fingers of the LIM domain (see Cofré et al. for more details [82]). 
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Figure 6. Active site structure of AGM from D. radiodurans. A and B represent the two 
Mn
2+
 binding sites (adapted from Ahn et al.[89]). 
 
Figure 7. ALP and AGM as promising targets for novel addiction treatments. AGM and 
ALP hydrolyse agmatine to urea and putrescine. The latter is further metabolized to 
spermine. An inhibition of these two enzymes thus has the same effect as direct agmatine 
injection. 
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